Preferred Label : almitrine;
MeSH definition : A respiratory stimulant that enhances respiration by acting as an agonist of peripheral
chemoreceptors located on the carotid bodies. The drug increases arterial oxygen tension
while decreasing arterial carbon dioxide tension in patients with chronic obstructive
pulmonary disease. It may also prove useful in the treatment of nocturnal oxygen desaturation
without impairing the quality of sleep.;
CISMeF synonym : 29608-49-9 (Almitrine dimesylate); servier brand of almitrine dimesilate; euthérapie brand of almitrine dimesilate;
MeSH hyponym : Almitrine Dimesylate; almitrine monomesylate; vectarion; Monomesylate, Almitrine; Almitrine Bis(methanesulfonate); Almitrine Bismesylate;
MeSH CAS label : 1,3,5-Triazine-2,4-diamine, 6-(4-(bis(4-fluorophenyl)methyl)-1-piperazinyl)-N,N'-di-2-propenyl-;
MeSH Related Number : almitrine monomesylate; almitrine dimesylate; 106648-10-6 (monomesylate); 27469-53-0 (Almitrine); 29608-49-9 (dimesylate); 6RY6V6XM8T;
Registry Number MeSH : 27469-53-0;
Related CAS MeSH : 106648-10-6 (Almitrine monomesylate); 6RY6V6XM8T (Almitrine dimesylate);
Codes EINECS : 248-475-5;
Is substance : O;
UNII : 9A1222NBG4;
InChIKey : OBDOVFRMEYHSQB-UHFFFAOYSA-N;
Origin ID : D015765;
UMLS CUI : C0002164;
ATC code(s)
Allowable qualifiers
Automatic exact mappings (from CISMeF team)
CISMeF manual mappings
Currated CISMeF NLP mapping
Pharmacological action(s)
Record concept(s)
Related MeSH Supplementary Concept(s)
- S 1867 [MeSH Supplementary Concept]
- S 9581 [MeSH Supplementary Concept]
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
A respiratory stimulant that enhances respiration by acting as an agonist of peripheral
chemoreceptors located on the carotid bodies. The drug increases arterial oxygen tension
while decreasing arterial carbon dioxide tension in patients with chronic obstructive
pulmonary disease. It may also prove useful in the treatment of nocturnal oxygen desaturation
without impairing the quality of sleep.
https://www.has-sante.fr/jcms/p_3242559/fr/vectarion
2021
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
treatment outcome
-
infusions, intravenous
almitrine
almitrine
respiratory system agents
Respiratory Distress Syndrome
respiration, artificial
combined modality therapy
Adjuvant therapy
Almitrine Dimesylate
---
http://www.has-sante.fr/portail/jcms/c_1525570/vectarion
http://www.has-sante.fr/portail/upload/docs/evamed/CT-12442_VECTARIONinjectable_saisine_Avis2_CT12442.pdf
2013
France
French
evaluation of the transparency committee
Almitrine Dimesylate
almitrine
infusions, intravenous
almitrine
-
respiratory system agents
Hypoxia
hypoxemia
hypercapnia
treatment outcome
---
http://www.cochrane.org/fr/CD008068
2011
United Kingdom
France
French
meta-analysis
dementia
treatment outcome
drug combinations
yohimbine
neuroprotective agents
almitrine, raubasine drug combination
raubasine
almitrine
secologanin tryptamine alkaloids
french abstract
---
http://www.has-sante.fr/portail/jcms/c_1098682/vectarion
http://www.has-sante.fr/portail/jcms/c_1098791/vectarion-ct11279
http://www.has-sante.fr/portail/jcms/c_1079013/vectarion
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-11/vectarion_ct_10088.pdf
http://www.has-sante.fr/portail/jcms/c_574653/vectarion
http://www.has-sante.fr/portail/jcms/c_399049/vectarion-50-mg-comprime-pellicule-secable-boite-de-30
2011
France
French
English
evaluation of the transparency committee
almitrine
administration, oral
-
almitrine
respiratory system agents
respiratory insufficiency
bronchitis, chronic
Hypoxia
treatment outcome
---